Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Disease detection methodologies in relapsed B-cell acute lymphoblastic leukemia: Opportunities for improvement.
Shalabi H, Yuan CM, Kulshreshtha A, Dulau-Florea A, Salem D, Gupta GK, Roth M, Filie AC, Yates B, Delbrook C, Derdak J, Mackall CL, Lee DW, Fry TJ, Wayne AS, Stetler-Stevenson M, Shah NN. Shalabi H, et al. Pediatr Blood Cancer. 2020 Apr;67(4):e28149. doi: 10.1002/pbc.28149. Epub 2020 Jan 25. Pediatr Blood Cancer. 2020. PMID: 31981407 Free PMC article.
Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.
Chihara D, Arons E, Stetler-Stevenson M, Yuan CM, Wang HW, Zhou H, Raffeld M, Xi L, Steinberg SM, Feurtado J, James L, Wilson W, Braylan RC, Calvo KR, Maric I, Dulau-Florea A, Kreitman RJ. Chihara D, et al. J Clin Oncol. 2020 May 10;38(14):1527-1538. doi: 10.1200/JCO.19.02250. Epub 2020 Feb 28. J Clin Oncol. 2020. PMID: 32109194 Free PMC article. Clinical Trial.
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.
Shah NN, Highfill SL, Shalabi H, Yates B, Jin J, Wolters PL, Ombrello A, Steinberg SM, Martin S, Delbrook C, Hoffman L, Little L, Ponduri A, Qin H, Qureshi H, Dulau-Florea A, Salem D, Wang HW, Yuan C, Stetler-Stevenson M, Panch S, Tran M, Mackall CL, Stroncek DF, Fry TJ. Shah NN, et al. J Clin Oncol. 2020 Jun 10;38(17):1938-1950. doi: 10.1200/JCO.19.03279. Epub 2020 Apr 14. J Clin Oncol. 2020. PMID: 32286905 Free PMC article. Clinical Trial.
Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients.
Ishii K, Pouzolles M, Chien CD, Erwin-Cohen RA, Kohler ME, Qin H, Lei H, Kuhn S, Ombrello AK, Dulau-Florea A, Eckhaus MA, Shalabi H, Yates B, Lichtenstein DA, Zimmermann VS, Kondo T, Shern JF, Young HA, Taylor N, Shah NN, Fry TJ. Ishii K, et al. J Clin Invest. 2020 Oct 1;130(10):5425-5443. doi: 10.1172/JCI130059. J Clin Invest. 2020. PMID: 32925169 Free PMC article.
Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma.
Kazandjian D, Dew A, Hill E, Ramirez EG, Morrison C, Mena E, Lindenberg L, Yuan C, Maric I, Wang HW, Calvo K, Dulau-Florea A, Roswarski J, Emanuel M, Braylan R, Turkbey B, Choyke P, Camphausen K, Stetler-Stevenson M, Steinberg SM, Figg WD, C Jones J. Kazandjian D, et al. Oncologist. 2021 Apr;26(4):288-e541. doi: 10.1002/onco.13712. Epub 2021 Mar 10. Oncologist. 2021. PMID: 33554406 Free PMC article. Clinical Trial.
Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells.
Lichtenstein DA, Schischlik F, Shao L, Steinberg SM, Yates B, Wang HW, Wang Y, Inglefield J, Dulau-Florea A, Ceppi F, Hermida LC, Stringaris K, Dunham K, Homan P, Jailwala P, Mirazee J, Robinson W, Chisholm KM, Yuan C, Stetler-Stevenson M, Ombrello AK, Jin J, Fry TJ, Taylor N, Highfill SL, Jin P, Gardner RA, Shalabi H, Ruppin E, Stroncek DF, Shah NN. Lichtenstein DA, et al. Blood. 2021 Dec 16;138(24):2469-2484. doi: 10.1182/blood.2021011898. Blood. 2021. PMID: 34525183 Free PMC article. Clinical Trial.
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.
Kazandjian D, Hill E, Dew A, Morrison C, Roswarski J, Korde N, Emanuel M, Petrosyan A, Bhutani M, Calvo KR, Dulau-Florea A, Kwok M, Lee MJ, Lee S, Lindenberg L, Mailankody S, Manasanch E, Maric I, Mena E, Patel N, Tageja N, Trepel JB, Turkbey B, Wang HW, Wang W, Yuan C, Zhang Y, Braylan R, Choyke P, Stetler-Stevenson M, Steinberg SM, Figg WD Sr, Roschewski M, Landgren O. Kazandjian D, et al. JAMA Oncol. 2021 Nov 1;7(11):1678-1685. doi: 10.1001/jamaoncol.2021.3971. JAMA Oncol. 2021. PMID: 34529025 Free PMC article. Clinical Trial.
Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant.
Chihara D, Arons E, Stetler-Stevenson M, Yuan C, Wang HW, Zhou H, Raffeld M, Xi L, Steinberg SM, Feurtado J, James-Echenique L, Tai CH, Patel KP, Braylan RC, Calvo KR, Maric I, Dulau-Florea A, Kreitman RJ. Chihara D, et al. Blood Adv. 2021 Dec 14;5(23):4807-4816. doi: 10.1182/bloodadvances.2021005039. Blood Adv. 2021. PMID: 34607348 Free PMC article. Clinical Trial.
Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia.
Groarke EM, Patel BA, Shalhoub R, Gutierrez-Rodrigues F, Desai P, Leuva H, Zaimoku Y, Paton C, Spitofsky N, Lotter J, Rios O, Childs RW, Young DJ, Dulau-Florea A, Dunbar CE, Calvo KR, Wu CO, Young NS. Groarke EM, et al. Among authors: dulau florea a. Leukemia. 2022 Sep;36(9):2328-2337. doi: 10.1038/s41375-022-01636-8. Epub 2022 Jul 27. Leukemia. 2022. PMID: 35896822 Free PMC article.
35 results